Clinical trial
First in Human, Phase Ia/Ib Study for Safety, Tolerability, Pharmacokinetics, and Clinical Activity Evaluation of ADEL-Y01 in Healthy Participants and in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
NCT06247345 is registered in ClinicalTrials.gov with Alzheimer's Disease Expert Lab (ADEL), Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- First in Human, Phase Ia/Ib Study for Safety, Tolerability, Pharmacokinetics, and Clinical Activity Evaluation of ADEL-Y01 in Healthy Participants and in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
- Lead sponsor
- Alzheimer's Disease Expert Lab (ADEL), Inc.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- February 6, 2024
- Completion date
- January 7, 2026
- Enrollment
- 42 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.